| Andrew Scott Westhora, RPH | |
|
4855 Sw Western Ave, Beaverton, OR 97005-3460 | |
| (503) 495-6622 | |
| Not Available |
| Full Name | Andrew Scott Westhora |
|---|---|
| Gender | Male |
| Speciality | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist |
| Location | 4855 Sw Western Ave, Beaverton, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356525752 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P0018X | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist | RPH-0010661 (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Andrew Scott Westhora, RPH 4855 Sw Western Ave, Beaverton, OR 97005-3460 Ph: (503) 495-6622 | Andrew Scott Westhora, RPH 4855 Sw Western Ave, Beaverton, OR 97005-3460 Ph: (503) 495-6622 |
News Archive
The association between post-traumatic stress disorder and mental health-related quality of life among individuals with bipolar disorder may be mediated by depressive symptoms, the results of a US study indicate.
A recent study from Japan available reveals how almost all cases of coronavirus disease (COVID-19) among domestic animals can be linked to their owners infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Seattle Genetics, Inc. today announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS (brentuximab vedotin) from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma.
The ATS Foundation is pleased to announce the new ATS Foundation/Fisher & Paykel Healthcare Research Award in Respiratory Support with Nasal High Flow in Patients with COPD. The award will provide funding for two years in the amount of $100,000.
Shire plc, the global specialty biopharmaceutical company, today announced the results of a study evaluating the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder in adolescents aged 13 to 17 years.
› Verified 4 days ago
Laura Veriga, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 11425 Sw Beaverton Hillsdale Hwy, Beaverton, OR 97005 Phone: 503-526-1833 Fax: 503-526-1839 | |
Diane Pham, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 14625 Sw Allen Blvd, Beaverton, OR 97007 Phone: 714-204-9190 | |
Dr. Tahmeena Raheel, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 10775 Sw Beaverton Hillsdale Hwy, Beaverton, OR 97005 Phone: 503-207-0646 | |
Ola D Hanna, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 14600 Sw Murray Scholls Dr, Beaverton, OR 97007 Phone: 503-579-1878 | |
Andre Vo, PHARM. D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2575 Sw Walker Rd, Beaverton, OR 97005 Phone: 503-646-2423 | |
Wu Cheng Li, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 18101 Nw Evergreen Pkwy, Beaverton, OR 97006 Phone: 503-207-0041 | |
Dr. Joanna Renee Zumbrun, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 9055 Sw Murray Blvd, Beaverton, OR 97008 Phone: 503-207-2554 Fax: 503-207-2554 |